Page last updated: 2024-10-28

gyki 52466 and Chronic Disease

gyki 52466 has been researched along with Chronic Disease in 2 studies

GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Kim, JE1
Park, H1
Lee, JE1
Kim, TH1
Kang, TC1
Farley, S1
Apazoglou, K1
Witkin, JM1
Giros, B1
Tzavara, ET1

Other Studies

2 other studies available for gyki 52466 and Chronic Disease

ArticleYear
PTEN Is Required for The Anti-Epileptic Effects of AMPA Receptor Antagonists in Chronic Epileptic Rats.
    International journal of molecular sciences, 2020, Aug-06, Volume: 21, Issue:16

    Topics: Animals; Benzodiazepines; Chronic Disease; Down-Regulation; Epilepsy; Hippocampus; Male; Models, Bio

2020
Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm.
    The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:9

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzodiazepines; Chronic Disease; Depression; Depr

2010
chemdatabank.com